scPharma Q1 net loss $14.1M; FUROSCIX revenue $6.1M, doses written up 28% QoQ

scPharmaceuticals Inc.

2024-Q1 EPS reported -$0.36 revenue$6,102,000

Net FUROSCIX revenue $6.1M vs $2.1M in Q1 2023; gross-to-net discount 19%.
Net loss $14.1M vs $11.2M; cash and equivalents $58.4M at quarter end.
17,376 doses written (+28% QoQ); 8,074 filled (+15% QoQ); 2,938 in-services completed.
Change Healthcare cyberattack estimated 10% negative impact on doses filled in Q1.
FDA PDUFA date August 2024 for Class IV HF indication; PK study for auto-injector underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

scPharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $6.1 million, net income $14.1 million.

Period: first quarter ended March 31, 2024
Revenue: $6.1 million
Net income: $14.1 million
Result: reported results

Exact text from the filing

(EX-99.1) --- EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-138214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.